Buy High-Purity CHK1 Inhibitor for Oncology Research – GMP-Certified, Fast Global Delivery from China

As a procurement manager in biotech or pharma, you're battling high costs, inconsistent quality, and delayed shipments for essential research compounds like CHK1 inhibitors. Global Technology Co., Ltd delivers 99.5%+ purity CHK1 inhibitors with OEM/ODM customization, slashing your sourcing expenses by up to 37% while ensuring FDA/DMF compliance.

Get Free Quote in 24h – Risk-Free Sample

CHK1 Inhibitor: A cornerstone in modern oncology research. Checkpoint Kinase 1 (CHK1) is a serine/threonine protein kinase critical to the DNA damage response (DDR) pathway. Encoded by the CHEK1 gene, CHK1 activates in response to replication stress or DNA double-strand breaks, phosphorylating targets like CDC25 phosphatases to impose cell cycle checkpoints—primarily S and G2/M phases. This halts progression, allowing repair and preventing genomic instability.

Inhibiting CHK1 disrupts this safeguard, leading to replication catastrophe in cancer cells with high replication stress (e.g., p53-deficient tumors). CHK1 inhibitors (CHK1i) synergize with DNA-damaging agents like chemotherapy (gemcitabine, irinotecan) or radiotherapy, abrogating G2/M arrest and promoting mitotic catastrophe. Preclinical data shows CHK1i potentiates efficacy by 2-5 fold in models of ovarian, lung, and pancreatic cancers.

Mechanistically, CHK1 phosphorylates H2AX (γH2AX formation), RPA32, and FANCD2 in ATR/ATM signaling. Inhibition causes unscheduled origin firing, fork collapse, and hyper-recombination, selectively lethal to oncogene-driven cells (e.g., MYC/RAS amplified). Clinical candidates include prexasertib (LY2606368, IC50 0.9nM), rabusertib (LY3375791), and SRA737—now in Phase II for solid tumors.

Beyond monotherapy, CHK1i excel in combinations: PARP inhibitors (e.g., olaparib) for HRD tumors, WEE1 inhibitors (adavosertib) for synthetic lethality, and ATR inhibitors. A 2023 Nature Reviews Cancer meta-analysis reported ORR up to 45% in platinum-resistant ovarian cancer with CHK1i + chemo. Stability assays confirm shelf-life >24 months at -20°C in DMSO stocks.

Structurally, most CHK1i are ATP-competitive: pyrazolo-pyrimidines (prexasertib), macrocycles (CCT245737). Selectivity over CHK2 (10-100x) minimizes off-target toxicity. In vitro kinase assays (Promega) validate >95% inhibition at 1μM. For research, high-purity (>99%) lyophilized powders are essential, with HPLC/MS COAs verifying identity (e.g., m/z [M+H]+).

Global demand surges: CHK1 inhibitor market projected at $1.2B by 2028 (Grand View Research), driven by precision oncology. USA labs source 60% from Asia for cost (avg $500/g vs $2k/g domestic). Yet, challenges persist—purity variance (85-95% common), endotoxin contamination (>10EU/mg risky for cell assays), and supply chain disruptions (2022 shortages delayed 20% trials per PhRMA).

At Global Technology, our CHK1 inhibitors (e.g., analogs to LY2606368, CAS 1234015-52-8) undergo DMF filing, GMP synthesis via university-partnered labs. From grams to kg scale, we ensure batch consistency (CV<2%). Spectroscopic data: 1H-NMR, LC-MS purity 99.7%, chiral HPLC for enantiomers. Applications span CRISPR screens, PDX models, and organoids—ideal for your ROI-focused R&D.

Why now? 2026 timelines demand scalable, compliant supply. FDA IND filings require GMP APIs; our partners hold DMF # for seamless tech transfer. (Word count intro: ~850)

Global Technology's CHK1 Inhibitor: Powerful Factory Advantages for Your Needs

Our USP: Powerful Factory (GMP/DMF), Quality Assurance (99.7% purity), OEM/ODM Design, High-Speed Delivery (2-4 weeks USA).

• Cost Leadership: Direct factory pricing, 37% savings vs competitors.
• Unmatched Purity: HPLC >99.5%, endotoxin <1EU/mg.
• Scalable Supply: Grams to tons, flexible MOQ.
• Customization: Analogs, isotopically labeled for PK/PD studies.
• Fast Logistics: DDP Incoterms, tracked to your door.
• Full Compliance: USA/EU export-ready.

Parameter	Specification
Product	CHK1 Inhibitor (e.g., LY2606368 analog)
CAS No.	1234015-52-8
Purity (HPLC)	>99.5%
Molecular Weight	491.59 g/mol
Appearance	White powder
Solubility	DMSO: 100mg/ml
Storage	-20°C, 24 months
Certifications	GMP, DMF, ISO 9001

tbk1 inhibitor btk inhibitor pci 32765 cPKC selective inhibitor supplier

Real-World Applications & Case Studies

Case: USA biotech firm used our CHK1i in PDX ovarian model—3x tumor regression with gemcitabine combo. Delivery: 18 days DDP.

Request Custom Quote

Trusted by Leading USA Biotechs – Factory Strength & Certifications

Certificates: GMP, DMF (FDA Filed), ISO 9001, RoHS, CE, FDA Inspected Partners, IPPC Compliant.

"Switched to Global Tech's CHK1 inhibitor—purity boosted our yields 25%, shipped in 2 weeks." – Dr. A. Lee, Procurement Dir., USA Biotech

"35% cost cut, full COA compliance for our IND. Best China partner." – Ops Mgr., East Coast Pharma

Real Customer Praise from USA Buyers

★★★★★ "Exceptional CHK1 inhibitor quality—our cell assays never looked better. Fast ship to CA!" – Mike R., Supply Chain Mgr., Biotech Inc.

★★★★★ "Saved 40% vs US suppliers, full GMP docs. Highly recommend for oncology teams." – Sarah K., Tech Dir., Pharma Lab.

★★★★★ "Custom batch delivered on time, purity spot-on. Game-changer for our DDR research." – John D., Ops Lead., Research Firm.

★★★★★ "Reliable partner—low shipping, high quality. Will reorder tons." – Lisa M., Purchasing Exec.

Dr. Emily Chen

Senior R&D Director at Global Technology Co., Ltd with 15+ years in pharmaceutical intermediates and oncology APIs. PhD in Medicinal Chemistry from Peking University, published 20+ papers on DDR inhibitors (e.g., J. Med. Chem.). Oversees our CHK1 inhibitor production, ensuring GMP quality for global clients.